Treatment for Metastatic HER2 Breast Cancer
Reporter: Larry H Bernstein, MD, FCAP
Leaders in Pharmaceutical Innovation
http://pharmaceuticalintelligence.com/2013/03/03/9680/Treatment for Metastatic HER2 Breast Cancer
The US Food and Drug Administration (FDA) today approved ado-trastuzumab emtansine (Kadcyla, Genentech), also known as T-DM1, for the treatment of patients with HER2-positive metastatic breast cancer.
T-DM1 is indicated for patients who were previously treated with
- the anti-HER2 therapy trastuzumab (Herceptin, Genentech) and a taxane chemotherapy.
This product offers a new twist on an older product; it is an antibody–drug conjugate in which the
View original post 295 more words